## FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPE	ROVAL
OMB Number:	3235-0287
Estimated average	burden
hours par response	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

		/													
Name and Address of Reporting Person *  Trombly Amy Moss				2. Issuer Name and Ticker or Trading Symbol Sonoma Pharmaceuticals, Inc. [SNOA]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director I 0% Owner Officer (give title below) Chief Executive Officer					
(Last) (First) (Middle) C/O SONOMA PHARMACEUTICALS, INC., 645 MOLLY LANE, SUITE 150				3. Date of Earliest Transaction (Month/Day/Year) 01/14/2022										7)	
(Street) WOODSTOCK, GA 30189				4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person _Form filed by More than One Reporting Person					
(City) (State) (Zip)				Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned											
1.Title of S (Instr. 3)	ecurity		2. Transaction Date (Month/Day/Year)		on Da	ate, if (		8) (1	A) or Disposed constr. 3, 4 and 5)  (A) or (D)	of (D) Ov Tra	Amount of S wned Follow ansaction(s) astr. 3 and 4)		d	Ownership Form:	7. Nature of Indirect Beneficial Ownership Instr. 4)
								in this t display uired, Dispo	s who respond form are not read as a currently was	equired to valid OMI	o respond B control r	unless the		ed SEC 1	474 (9-02)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if	4. Transac Code	tion (	<b>lls, warı</b> 5. Numb	er ative es d (A) sed	in this t display uired, Dispo options, co	osed of, or Bene nvertible securiorisable and Date	equired to valid OMI	o respond B control r wned and Amount lying	unless the umber.		of 10. Ownersh Form of Derivativ Security: Direct (I or Indirec	11. Natur of Indirec Beneficia Ownersh (Instr. 4)
Derivative Security	Conversion or Exercise Price of Derivative	Date	3A. Deemed Execution Date, if any	4. Transac Code	tion (	Ils, warn 5. Numb of Derive Securitie Acquired or Dispo of (D) (Instr. 3,	rants, eer ative es d (A) sed 4,	in this in display uired, Disposorous, co	sed of, or Bene nvertible securiorcisable and Date y/Year)	equired to valid OMI  ficially Orities)  7. Title an of Underly Securities	o respond B control r wned and Amount lying	8. Price of Derivative Security	9. Number of Derivative Securities Beneficially Owned Following Reported	of 10. Ownersh Form of Derivativ Security: Direct (I or Indirec	11. Natur of Indirec Beneficia Ownersh (Instr. 4)

#### **Reporting Owners**

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Trombly Amy Moss C/O SONOMA PHARMACEUTICALS, INC. 645 MOLLY LANE, SUITE 150 WOODSTOCK, GA 30189			Chief Executive Officer			

### **Signatures**

/s/ Amy Trombly	01/14/2022
**Signature of Reporting Person	Date

#### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The options vest 10,000 each on 07/14/2022, 07/14/2023 and 07/14/2024, or upon change of control.

(2) The options were awarded and granted to Ms. Trombly for services performed.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.